Fenwick has advised Scribe Therapeutics. Latham & Watkins has advised the underwriters. Scribe Therapeutics Inc., a clinical-stage biotechnology company specializing in in vivo CRISPR technologies, has...
Scribe Therapeutics Completes $155.51 Million Initial Public Offering and Private Placement
Viking Completes US$1.7 Billion Senior Notes Offering
Latham & Watkins LLP has advised the initial purchasers. Bratschi has advised Viking. Milbank LLP has advised the issuer. Viking Holdings Ltd, listed on the NYSE...
Viking Holdings Completes $1.3 Billion Secondary Public Offering
Milbank advised Viking Holdings on the transaction, Ropes & Gray advised selling shareholders TPG Capital and the Canada Pension Plan Investment Board. Latham & Watkins represented...
Carlyle and SK Capital’s Acquisition of bluebird bio
Wachtell, Lipton, Rosen & Katz, Kirkland & Ellis, and Orrick, Herrington & Sutcliffe are serving as legal advisors to Carlyle and SK Capital, while Latham &...
LetsGetChecked’s Acquisition of Truepill
Goodwin Procter, McDermott Will & Emery, and Mason Hayes & Curran advised LetsGetChecked, while Latham & Watkins and BakerHostetler advised Truepill on the deal. LetsGetChecked, a...
Viking Holdings’ $1.07 Billion Ordinary Shares Offering
Milbank advised Viking Holdings Ltd on the offering, Latham & Watkins advised the underwriters and Ropes & Gray advised the selling shareholders. Viking Holdings Ltd (NYSE:...
Latham & Watkins Names 34 New Partners and 48 New Counsel
Latham & Watkins LLP is pleased to announce that 34 associates have been elected to the partnership and another 48 associates have been promoted to the […]
Mineralys Therapeutics’ $192 Million Initial Public Offering
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
CG Oncology’s $120 Million Series E Financing Round
Latham & Watkins LLP represented CG Oncology in the transaction. CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic...
HilleVax’s $200 Million Initial Public Offering
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
Ligand’s Spin-off of OmniAb Business
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...
Icosavax’s $100 Million Series B Financing
Latham & Watkins LLP represented Icosavax, Inc. in the transaction. Icosavax, Inc. closed a US$100 million Series B Financing, led by RA Capital Management and joined by...